National Institute of Allergy and Infectious Diseases (NIAID): all 2,445 studies

Page 19 of 25. Open to participants first (182), then studies with results posted, then the rest; newest registration first within each.

• HIV Maintenance Therapy With T-20 During HAART InterruptionCompletedNCT00013884Phase 2
• Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV DrugsCompletedNCT00013871Not applicable
• Adefovir Dipivoxil to Treat Hepatitis B in HIV-Infected PatientsCompletedNCT00013702Phase 2
• Pyrimethamine and Sulfadoxine for Treatment of Autoimmune Lymphoproliferative SyndromeCompletedNCT00013689Phase 1
• Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral LoadCompletedNCT00013663Phase 2
• Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV PatientsCompletedNCT00013585Phase 2
• Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV InfectionCompletedNCT00013520Phase 3
• Ritonavir and Indinavir in Children Failing Other Anti-HIV TreatmentCompletedNCT00012519Phase 1/2
• Blood Levels of Abacavir After One Dose in HIV-Infected Children and AdolescentsCompletedNCT00011479Phase 1
• Salvage Treatment, Resistance Testing, and Withdrawal of Anti-HIV Drugs for HIV Patients Failing Current Anti-HIV TreatmentWithdrawnNCT00011128Phase 3
• Effects of Storage on Lactate in Blood SamplesCompletedNCT00011050
• ALVAC-HIV vCP1452 Alone and Combined With MN rgp120CompletedNCT00011037Phase 2
• Vaccine (ALVAC-HIV vCP1452) Use and Intermittent Withdrawal of Anti-HIV Drugs in Patients With HIVCompletedNCT00011011Phase 1/2
• HIV-1 Vaccine Test in Uninfected Adult VolunteersCompletedNCT00009685Phase 1
• Testosterone for HIV-Positive Men With Reduced Serum Testosterone Levels and Abdominal FatCompletedNCT00009555Phase 4
• Analysis of HIV Genetic Variation in Patients Before Beginning Highly Active Antiretroviral TherapyCompletedNCT00009256
• Effectiveness of Early or Delayed Addition of Hydroxyurea to a Three-Drug Anti-HIV Drug Combination Including Didanosine, in Advanced HIV Patients Who Failed a First or Second Anti-HIV Triple-Drug TherapyWithdrawnNCT00008866Phase 2
• Evaluation of Two Type III GBS Polysaccharide-Tetanus Toxoid Conjugate VaccinesCompletedNCT00008853Phase 1
• A Randomized, Open Label, Comparative, Multicenter Trial of Voriconazole Vs. AmBisome for Empirical Antifungal Therapy in Immunocompromised Patients With Persistent Fever and NeutropeniaCompletedNCT00008840
• A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)CompletedNCT00008463Phase 2
• Antibody and Delayed Cyclosporine Versus Initial Cyclosporine Alone in Patients Receiving Kidney TransplantsCompletedNCT00007787Not applicable
• HIV in Specific Parts of the Body of Patients Who Are Changing or Starting Potent Anti-HIV DrugsCompletedNCT00007488
• Safety and Effectiveness of the Vaccine ALVAC-HIV vCP205 in HIV-Negative Adult Volunteers in UgandaCompletedNCT00007423Phase 1
• Safety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination With AIDSVAX B/BCompletedNCT00007332Phase 2
• Carotid Artery Thickness in HIV Infected and Uninfected AdultsCompletedNCT00007319
• Safety and Effectiveness of a Three-Drug Combination Treatment for Recently Infected or Converted HIV PatientsCompletedNCT00007202Phase 2
• Monoclonal Antibody Treatment of Crohn's DiseaseCompletedNCT00007163Phase 1
• Comparing Single Photon Emission Computed Tomography (SPECT) and Liver Biopsy to Evaluate the Liver in Patients With HIV and Hepatitis C VirusCompletedNCT00006643
• Vaccinia Immune Globulin in Treating or Preventing Vaccinal InfectionWithdrawnNCT00006630Phase 1
• Four-Drug Combination Therapy With Zidovudine, Lamivudine, 1592U89 (Abacavir), and 141W94 (Amprenavir) in HIV-Infected PatientsCompletedNCT00006617Not applicable
• Evaluation of Specific Infection-Fighting Cells For Prediction of Immune Response to Anti-HIV and Immune-Boosting MedicationWithdrawnNCT00006578Not applicable
• A Study of the Safety and Effectiveness of an HIV Vaccine for HIV-Positive Patients Receiving Anti-HIV Drugs for at Least 2 YearsCompletedNCT00006509Phase 1
• Immune Responses in HIV-Positive Patients Receiving an Anti-HIV Drug Combination When Given the HIV Vaccines Remune and vCP1452CompletedNCT00006495Phase 1
• Study of Tests to Evaluate Effectiveness of Anti-HIV DrugsCompletedNCT00006494
• A Comparison of Two Tests for Anti-HIV Drug ResistanceCompletedNCT00006490
• The Effects of Combination Anti-HIV Medication on Human Papillomavirus (HPV) in HIV-Infected WomenCompletedNCT00006444
• Effectiveness of Anti-HIV Drugs in Patients Who Have Not Received Previous Anti-HIV Drugs During Different Stages of HIV InfectionCompletedNCT00006443Not applicable
• The Effects of Anti-HIV Drugs on the HIV Virus in HIV-Infected PatientsCompletedNCT00006442
• Effectiveness of Adding Interleukin-2 to Anti-HIV Drugs in Patients Recently Infected With HIVCompletedNCT00006441Not applicable
• A Test of Behavioral Intervention for Women at High Risk for HIV InfectionCompletedNCT00006440
• Modified Stem Cell Transplantation Procedure for Treating Chronic Granulomatous DiseaseCompletedNCT00006417Phase 2
• A Study of Patients Who Recently Have Been Infected With HIVWithdrawnNCT00006415
• Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood LipidsCompletedNCT00006412Phase 3
• Effectiveness of AZT and Nevirapine in Preventing HIV Transmission From Ugandan Mothers to Their NewbornsCompletedNCT00006396Phase 3
• Safety and Effectiveness of an Anti-HIV Drug Combination With and Without Hydroxyurea in Patients With Early HIV InfectionWithdrawnNCT00006339Phase 2
• Safety, Tolerability, and Anti-HIV Activity of PEG-Intron in HIV-Positive ChildrenCompletedNCT00006325Phase 1
• Pharmacokinetics of Antiretroviral Agents in HIV-1 Infected Pregnant WomenCompletedNCT00006320Phase 1
• Withdrawal of Antifungal Treatment for Histoplasmosis in Patients After Improved Immune Response to Anti-HIV DrugsCompletedNCT00006316
• Long-Term Effects of HIV Exposure and Infection in ChildrenCompletedNCT00006304
• Studies of HIV-1 Infection in Newly Infected Individuals in Southern AfricaCompletedNCT00006298
• Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug CombinationCompletedNCT00006291Phase 2
• Perceived Changes in Body Build and Image in Patients Who Are Now Taking or Recently Have Stopped Taking Anti-HIV DrugsCompletedNCT00006290
• The Safety of Nevirapine When Given to Breast-Feeding Babies From Birth to Age 6 MonthsCompletedNCT00006279Phase 1
• Safety and Tolerability of the Vaginal Gel PRO 2000/5CompletedNCT00006207Phase 1
• A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV InfectionCompletedNCT00006154Phase 3
• Effectiveness of Adding Remune to Your Current Anti-HIV Drug CombinationTerminatedNCT00006153Phase 1
• A Study to See If Taking One or Two Extra Drugs Can Lower HIV Levels in Patients Who Have Failed Their Anti-HIV Drug TreatmentCompletedNCT00006152Phase 2
• Half-Dose Flu Vaccine Study in Healthy AdultsCompletedNCT00006146Phase 2
• Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIVCompletedNCT00006145Phase 3
• A Study of HIV-Disease Development in AgingCompletedNCT00006144Phase 2
• Growth Hormone Treatment of Children With HIV-Associated Growth FailureCompletedNCT00006143Not applicable
• A Study of Chlorhexidine in the Prevention of HIV-1 Transmission From Mothers to Their BabiesCompletedNCT00006075Phase 2
• Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune SystemsCompletedNCT00006066Phase 1
• The Effect of Anti-HIV Treatment on Body Characteristics of HIV-Infected ChildrenCompletedNCT00006064
• Learning and Behavior Problems in Children With Chronic Granulomatous Disease and Related DisordersCompletedNCT00005933
• Effects of Long-Term Treatment With Valaciclovir (Valtrex) on Epstein-Barr VirusCompletedNCT00005924
• A Comparison of Two Anti-HIV Treatment PlansCompletedNCT00005915
• Comparison of Immune Response to Booster Vaccines in Blood Transplant Patients and Healthy VolunteersCompletedNCT00005907
• Safety of the Candidate Vaccine C4-V3 Alone or With Interleukin-12 (IL-12) in HIV-Infected Patients Receiving Effective Anti-HIV Drug TherapyCompletedNCT00005779Phase 1
• Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative VolunteersCompletedNCT00005762Not applicable
• Effectiveness of Giving an HIV Vaccine (Remune) to HIV-Positive Patients Receiving an Anti-HIV Drug CombinationCompletedNCT00005758Phase 3
• Safety and Anti-HIV Activity of Capravirine Alone and in Combination With Other Anti-HIV DrugsCompletedNCT00005673Phase 1
• A Multicenter, Prospective, Randomized, Double-Blind Clinical Trial Comparing Itraconazole Oral Solution in Cyclodextrin to Placebo in the Treatment of AspergillomaCompletedNCT00005668Phase 2
• A Comparison of HIV-Infected Patients With and Without Opportunistic (AIDS-Related) InfectionCompletedNCT00005572
• Observing Patients With Early HIV InfectionCompletedNCT00005020
• Prevention of Kidney Transplant RejectionCompletedNCT00005010Phase 3
• Evaluation of the Safety of Varivax® in Pediatric Renal Transplant RecipientsTerminatedNCT00005009Phase 1
• Comparison of Immune Response in Normal Volunteers and Patients With Helminth InfectionsCompletedNCT00004996
• Phase II Study of Fluconazole for Lymphocutaneous and Visceral SporotrichosisCompletedNCT00004938Phase 2
• Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients Who Have Never Received Anti-HIV DrugsCompletedNCT00004855Not applicable
• Phase III Randomized, Double-Blind, Placebo-Controlled Study of Acellular and Whole-Cell Pertussis VaccinesCompletedNCT00004800Phase 3
• Phase III Randomized, Double-Blind, Placebo-Controlled Study of Acellular and Whole-Cell Pertussis VaccinesCompletedNCT00004799Phase 3
• Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in BrazilCompletedNCT00004755Phase 2
• Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With TuberculosisCompletedNCT00004736Phase 1
• The Effects of Anti-HIV Therapy on the Immune Systems of Children and Young Adults Infected With HIVCompletedNCT00004735Not applicable
• Comparison of Treatments to Maintain Disease Remission in Patients With Wegener's Granulomatosis and Related Vasculitis SyndromesCompletedNCT00004567Phase 2
• Comparison of Two Test Methods-NASBA and Antigenemia-for Detecting Cytomegalovirus InfectionCompletedNCT00001976
• Once-Daily Drug Regimen for HIV-Infected PatientsCompletedNCT00001968Phase 1
• Intermittent Versus Continuous Medication in the Treatment of HIVCompletedNCT00001967Phase 4
• Brain Tissue Swelling and Seizure Activity in Inactive CysticercosisCompletedNCT00001912
• Interleukin-12 in the Treatment of Severe Nontuberculous Mycobacterial InfectionsCompletedNCT00001911Phase 1
• Mechanisms of Allergen ImmunotherapyCompletedNCT00001910
• Phase II Efficacy Study of Aerosolized Recombinant Human IL-4 Receptor in AsthmaCompletedNCT00001909Phase 2
• T Cell Cytokine Changes During IL-4 Receptor Treatment for AsthmaCompletedNCT00001908
• Safety and Immunogenicity of a Vaccine for Cutaneous Leishmaniasis Using Recombinant Human Interleukin-12 and Aluminum Hydroxide Gel as AdjuvantsCompletedNCT00001906Phase 1
• Interferon Gamma to Treat Leukocyte Adhesion Deficiency Type ICompletedNCT00001905Phase 2
• Assessment of a B-Mode Ultrasound Technique for the Measurement of Carotid Artery Intima-Media ThicknessCompletedNCT00001904
• Prevention of RSV Infections in Bone Marrow Transplant RecipientsCompletedNCT00001903Phase 4
• Etanercept to Treat Wegener's GranulomatosisCompletedNCT00001901Phase 2
• Immune and Viral Status of HIV-Infected Patients After Stopping Combination Antiretroviral TherapyCompletedNCT00001899

← National Institute of Allergy and Infectious Diseases (NIAID) overview and focus areas